BioSpace News Archive

Drug Development

A Peony For Your Thoughts: May Brings Progress in Alzheimer’s Research

May has been fruitful for research into the prevention and diagnosis of Alzheimer’s disease, the mechanisms behind early symptoms and potential treatments.

May 6, 2022
·
4 min read
·
Jazmine Colatriano
Drug Development

Clotting Risks Cause FDA to Restrict Use of J&J Vaccine

Janssen’s COVID-19 vaccine is now limited to certain individuals ages 18 years and up after the FDA downgraded its emergency use authorization (EUA).

May 6, 2022
·
2 min read
·
Vanessa Doctor, RN
Business

Biogen Licensing Deal is Sweet Music for Bolstering MS Portfolio

Biogen is bolstering its multiple sclerosis (MS) pipeline through a licensing agreement with Maine-based MedRhythms for its investigational digital therapeutic, MR-004.

May 6, 2022
·
3 min read
·
Alex Keown
Deals

Like COVID, Life Science Industry Finances Gain and Lose Strength

Life Science industries are seeing massive financial fluctuations in how they’re handling the COVID-19 pandemic, but there is some optimism of a recovery by biopharma executives.

May 6, 2022
·
4 min read
·
Mark Terry
Career Advice

How to Ace an Interview, Explained by a Pharma Recruiter

We spoke with Alison Senkovich O’Sullivan, Senior Director of Human Resources at Athersys, about how to ace an interview and what candidates can do to prepare.

May 6, 2022
·
4 min read
·
Kaley Lefevre
Policy

SEC Tightens Screws on Chinese Companies with Delisting Efforts

The U.S. SEC continues to tighten the screws on Chinese companies, adding more than 80 companies to its expanding list of companies that might be dropped from U.S. stock exchanges.

May 6, 2022
·
3 min read
·
Mark Terry
Drug Development

Clinical Catch-Up: Pfizer’s Paxlovid Gaff, a Win for Medicago-GSK’s Vaccine

Pfizer’s Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.

May 6, 2022
·
9 min read
·
Mark Terry
Drug Development

BeiGene Reports Lucrative Q1 Amid SEC Audit

Despite a growing product revenue, Beigene reported a net loss of $434.4 million for the first quarter of 2022, as well as updates to its audit from the SEC.

May 6, 2022
·
2 min read
·
Hayley Shasteen
Drug Development

FDA Makes Pfizer, Myovant Wait on Approval For Myfembree

The FDA has extended the review period for Myfembree, following the supplemental New Drug Application from Pfizer and Myovant. Here’s more about this news.

May 6, 2022
·
2 min read
·
Alex Keown
Policy

Global COVID-19 Deaths Estimated at 14.9 Million

Despite having infinitely better global communications, exact figures are hard to come by for COVID-19 fatalities. Here’s a look at that story and more COVID-19 news.

May 6, 2022
·
6 min read
·
Mark Terry